GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » 5-Year Yield-on-Cost %

Relmada Therapeutics (Relmada Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics 5-Year Yield-on-Cost %?

Relmada Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Relmada Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



RLMD's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Relmada Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Relmada Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's 5-Year Yield-on-Cost % falls into.



Relmada Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Relmada Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Relmada Therapeutics  (NAS:RLMD) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Relmada Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (Relmada Therapeutics) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
Cedric O'gorman officer: Chief Medical Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa director, officer: Chief Executive Officer 138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly director 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel officer: EVP, Head of R&D 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence officer: Chief Financial Officer 3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo officer: Chief Medical Officer 71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar director P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas officer: President and CSO 7707 GATEWAY BLVD, NEWARK CA 94560

Relmada Therapeutics (Relmada Therapeutics) Headlines

From GuruFocus

Relmada Therapeutics Provides Corporate Update

By PRNewswire 01-04-2024